Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Teijin Pharma’s Osteoporosis Med Ostabalo Now Available in Japan
January 31, 2023
- AnGes to Start Japan PII for NF-κB Decoy Oligo for Lower Back Pain
January 31, 2023
- Rexulti Filed for Major Depressive Disorder in Japan: Otsuka
January 31, 2023
- Shionogi Logs Record Profits as Xocova Nets 100 Billion Yen from Govt Purchase: April-December
January 31, 2023
- UCB Files Bimzelx for Label Expansion in Psoriatic Arthritis and More
January 31, 2023
- Lecanemab Earns Priority Review in Japan, Eisai Aims for Approval by Year-End
January 31, 2023
- Takeda to Transfer MS Med Copaxone to Teva JV, 1st Patented Drug under 2020 Pact
January 30, 2023
- Estimated 21,528 Patients Given Xocova as of Jan. 22: Shionogi
January 30, 2023
- Lecanemab Application Accepted for Review in Europe; FY2023 Approval Eyed
January 30, 2023
- NanoCarrier to Shift Biz Model to mRNA Out-Licensing, Joins Forces with Axcelead
January 27, 2023
- Torii Acquires Japan Rights for Nogra Pharma’s Acne Drug
January 27, 2023
- Enhertu Wins EU Approval for HER2 Low Breast Cancer
January 27, 2023
- Shipments of All 6 Argatroban Products Suspended or Restricted in Japan
January 26, 2023
- Multifunctional Peptide Conjugate Meets Criteria in Joint Research: PeptiDream/Santen
January 26, 2023
- Ono/KSQ Therapeutics Tie Up for Cancer Drug Discovery
January 26, 2023
- Takeda Gets Rights to Hutchmed’s Colorectal Cancer Med Outside China
January 25, 2023
- Astellas to Divest Antifungal Micafungin to Sandoz for Up to US$75 Million Upfront
January 25, 2023
- Moderna, NCGM Ink MOU to Push mRNA-Based Healthcare
January 24, 2023
- J-Pharma’s Biliary Tract Cancer Med Hits Mark in Japan PII Study
January 24, 2023
- Alzheimer’s Drug Leqembi Now Available in US: Eisai/Biogen
January 24, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…